Kensington Investment Counsel’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$960K Sell
4,278
-1,741
-29% -$434K 0.46% 47
2025
Q4
$1.45M Sell
6,019
-694
-10% -$177K 0.59% 48
2025
Q3
$1.84M Sell
6,713
-385
-5% -$105K 0.75% 42
2025
Q2
$1.83M Sell
7,098
-29
-0.4% -$6.92K 0.79% 41
2025
Q1
$1.6M Sell
7,127
-137
-2% -$32K 0.71% 47
2024
Q4
$1.66M Sell
7,264
-33
-0.5% -$7.95K 0.69% 48
2024
Q3
$1.78M Buy
7,297
+25
+0.3% +$5.59K 0.74% 47
2024
Q2
$1.39M Sell
7,272
-2,798
-28% -$568K 0.62% 50
2024
Q1
$1.99M Buy
10,070
+704
+8% +$129K 0.91% 41
2023
Q4
$1.61M Buy
9,366
+133
+1% +$20.4K 0.84% 40
2023
Q3
$1.37M Buy
9,233
+3,784
+69% +$684K 0.85% 43
2023
Q2
$1.19M Sell
5,449
-82
-1% -$18.3K 0.75% 47
2023
Q1
$1.21M Sell
5,531
-548
-9% -$119K 0.91% 46
2022
Q4
$1.27M Hold
6,079
0.99% 45
2022
Q3
$1.33M Buy
6,079
+34
+0.6% +$7.74K 1.12% 43
2022
Q2
$1.27M Sell
6,045
-142
-2% -$30.2K 1.08% 41
2022
Q1
$1.5M Sell
6,187
-682
-10% -$165K 0.99% 48
2021
Q4
$1.79M Buy
+6,869
New +$1.78M 1.04% 45
2021
Q2
$1.47M Buy
5,945
+141
+2% +$29.6K 1.01% 49
2021
Q1
$1.13M Buy
5,804
+380
+7% +$76.2K 0.85% 58
2020
Q4
$1.15M Buy
+5,424
New +$1.08M 0.95% 55

Other funds holding RMD

Kensington Investment Counsel's RMD Position: Q1 2026 in Review

Kensington Investment Counsel reduced its ResMed (RMD) stake by 29% in Q1 2026, selling an estimated $434K and leaving 4,278 shares worth $960K. The position accounts for 0.46% of the portfolio, ranked #47.

Kensington Investment Counsel first reported a position in RMD in Q4 2020 and has held it in 21 quarters since. The position peaked at $1.99M in Q1 2024. 939 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Kensington Investment Counsel held 4,278 shares of ResMed worth $960K as of Q1 2026.
  • Kensington Investment Counsel sold 1,741 ResMed shares in Q1 2026, an estimated $434K.
  • ResMed made up 0.46% of Kensington Investment Counsel's portfolio in Q1 2026, its #47 holding.
  • Kensington Investment Counsel first reported a position in ResMed in Q4 2020 and has held it in 21 quarters since.
  • Kensington Investment Counsel's ResMed position peaked at $1.99M in Q1 2024.
  • 939 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Kensington Investment Counsel's 13F filing for Q1 2026, filed 19 May 2026.